Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cooperative Allosteric Transitions01:58

Cooperative Allosteric Transitions

8.8K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
8.8K
Cooperative Allosteric Transitions01:58

Cooperative Allosteric Transitions

3.1K
3.1K
Cooperative Allosteric Transitions01:58

Cooperative Allosteric Transitions

2.7K
2.7K
Cooperative Binding of Transcription Regulators02:13

Cooperative Binding of Transcription Regulators

7.4K
Transcriptional regulators bind to specific cis-regulatory sequences in the DNA to regulate gene transcription. These cis-regulatory sequences are very short, usually less than ten nucleotide pairs in length. The short length means that there is a high probability of the exact same sequence randomly occurring throughout the genome.  Since regulators can also bind to groups of similar sequences, this further increases the chances of random binding. Transcriptional regulators form...
7.4K
Cooperative Binding of Transcription Regulators02:13

Cooperative Binding of Transcription Regulators

2.6K
2.6K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

992
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
992

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk of metabolic dysfunction-associated steatotic liver disease and hepatic fibrosis: a large-scale study from the Middle East.

International journal of obesity (2005)·2026
Same author

A Comparison of the Effects of the Timing of Resistance Exercise on Glucose Levels Within the Target Range in People With Type 1 Diabetes (TREX Study): A Randomized Crossover Trial.

Diabetes/metabolism research and reviews·2026
Same author

Clinical profile, treatment practices, and complications in chronic hypoparathyroidism in a Middle Eastern cohort.

Journal of the Endocrine Society·2026
Same author

Effects of Bariatric Surgery and Obesity Medicines on Human Eating Behavior.

Annual review of nutrition·2026
Same author

Integrated Inflammatory Biomarker Profiling Differentiates Degrees of Body Mass Index Beyond Intestinal Barrier-Related Markers.

Cells·2026
Same author

Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial.

Lancet (London, England)·2026

Related Experiment Video

Updated: Feb 7, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.7K

Post-bariatric Hypoglycemia Management: A Gulf Cooperation Council Consensus Statement.

Elamin Abdelgadir1,2, Fauzia Rashid1,2, Fatheya Al Awadi1,2

  • 1Mohamed Bin Rashid University, Dubai 505055, UAE.

Journal of the Endocrine Society
|February 6, 2026
PubMed
Summary

Post-bariatric hypoglycemia (PBH) management is inconsistent due to complex causes and lack of standard treatments. This consensus provides unified, evidence-based guidelines for diagnosis and care.

Keywords:
GCCGulf regionPBHRYGBbariatric surgerydumping syndromemetabolic and bariatric surgeryobesitypost-bariatric hypoglycemiapostprandial

More Related Videos

Therapeutic Effectiveness of a Dietary Supplement for Management of Halitosis in Dogs
07:33

Therapeutic Effectiveness of a Dietary Supplement for Management of Halitosis in Dogs

Published on: July 6, 2015

12.0K
Laparoscopy-endoscopy Cooperative Surgery for the Treatment of Gastric Gastrointestinal Stromal Tumors
05:16

Laparoscopy-endoscopy Cooperative Surgery for the Treatment of Gastric Gastrointestinal Stromal Tumors

Published on: February 19, 2022

6.6K

Related Experiment Videos

Last Updated: Feb 7, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.7K
Therapeutic Effectiveness of a Dietary Supplement for Management of Halitosis in Dogs
07:33

Therapeutic Effectiveness of a Dietary Supplement for Management of Halitosis in Dogs

Published on: July 6, 2015

12.0K
Laparoscopy-endoscopy Cooperative Surgery for the Treatment of Gastric Gastrointestinal Stromal Tumors
05:16

Laparoscopy-endoscopy Cooperative Surgery for the Treatment of Gastric Gastrointestinal Stromal Tumors

Published on: February 19, 2022

6.6K

Area of Science:

  • Metabolic and Bariatric Surgery
  • Endocrinology
  • Gastroenterology

Background:

  • Post-bariatric hypoglycemia (PBH) is a significant late complication following metabolic and bariatric surgery.
  • PBH presents with a spectrum of symptoms, from mild to severe neuroglycopenic events.
  • Current PBH management is heterogeneous due to complex pathophysiology and lack of standardized protocols.

Purpose of the Study:

  • To establish a unified, evidence-based, and patient-centered management protocol for PBH.
  • To standardize the diagnosis and treatment of PBH across clinical practice.
  • To address the heterogeneity in PBH management approaches.

Main Methods:

  • A panel of 16 international experts (GCC and Europe) conducted a literature review.
  • Consensus statements were developed using the Delphi method.
  • 45 statements were agreed upon, covering diagnosis, dietary management, education, and treatment.

Main Results:

  • Consensus was reached on 45 statements for comprehensive PBH management.
  • Guidelines cover diagnosis, dietary adjustments, patient education, and pharmacological treatment.
  • Special considerations for pregnancy, long-term monitoring, and clinical practice are included.

Conclusions:

  • Implementation of these consensus statements will standardize PBH management.
  • Significant gaps remain, including the need for PBH-specific therapies and robust clinical trials.
  • Future research should focus on addressing these identified gaps in PBH care.